Rhenman & Partners Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-130,000	Closed	-$5.63M	–	93
2020 Q4	$5.63M	Buy	130,000 +40,000	+44%	+$1.58M	0.46%	64
2020 Q3	$3.15M	Hold	90,000	–	–	0.28%	72
2020 Q2	$4.81M	Sell	90,000 -20,000	-18%	-$926K	0.52%	62
2020 Q1	$3.9M	Sell	110,000 -50,000	-31%	-$2.31M	0.55%	56
2019 Q4	$7.64M	Sell	160,000 -85,002	-35%	-$3.21M	0.84%	50
2019 Q3	$7.94M	Buy	245,002 +45,002	+23%	+$1.86M	1%	41
2019 Q2	$9.98M	Buy	200,000 +72,988	+57%	+$3.9M	1.1%	37
2019 Q1	$8.57M	Hold	127,012	–	–	1%	43
2018 Q4	$5.86M	Sell	127,012 -18,416	-13%	-$1.14M	0.67%	54
2018 Q3	$11.2M	Sell	145,428 -15,000	-9%	-$1.21M	1.12%	42
2018 Q2	$13.5M	Buy	160,428 +65,428	+69%	+$5.71M	1.38%	33
2018 Q1	$7.77M	Sell	95,000 -5,000	-5%	-$386K	0.96%	45
2017 Q4	$5.72M	Buy	100,000 +85,000	+567%	+$5.35M	0.77%	51
2017 Q3	$1M	Buy	+15,000	New	+$901K	0.13%	80

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rhenman & Partners Asset Management's AGIO Position: Q1 2021 in Review

Rhenman & Partners Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2021, closing a stake of 130,000 shares — an estimated $5.63M sold.

Rhenman & Partners Asset Management first reported a position in AGIO in Q3 2017 and held it in 14 quarters. The position peaked at $13.5M in Q2 2018. 174 funds tracked by Wall St. Rank hold AGIO as of Q1 2021.

Rhenman & Partners Asset Management reported no remaining Agios Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Rhenman & Partners Asset Management sold 130,000 Agios Pharmaceuticals shares in Q1 2021, an estimated $5.63M.
Rhenman & Partners Asset Management first reported a position in Agios Pharmaceuticals in Q3 2017 and held it in 14 quarters.
Rhenman & Partners Asset Management's Agios Pharmaceuticals position peaked at $13.5M in Q2 2018.
174 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.